ライフサイエンスコーパス: radiotracer

1 s ((18)F-FDG, (99m)Tc-rhAnnexin V-128, or no radiotracer).

2 h-quality second-generation TSPO-binding PET radiotracer.

3 F to a carbon in the organic backbone of the radiotracer.

4 ramycin demonstrated specific binding of the radiotracer.

5 FSPG images to evaluate the kinetics of this radiotracer.

6 d binding in the dorsal striatum with either radiotracer.

7 ther studied to evaluate it as a PET imaging radiotracer.

8 6.2 d (range, 0-13 d) after injection of the radiotracer.

9 y or late time points after injection of the radiotracer.

10 the sand patties as shown with a (35)SO4(2-) radiotracer.

11 limited by local retention of cell-effluxed radiotracer.

12 essed using (99m)Tc-linear duramycin control radiotracer.

13 ormed to assess beta-cell selectivity of the radiotracer.

14 a rise in hypoxia-mediated entrapment of the radiotracer.

15 escribed herein was to identify such a novel radiotracer.

16 nts relative to healthy controls with 2 TSPO radiotracers.

17 n CT and low uptake in the lung for both PET radiotracers.

18 l molecules to generate disease specific PET radiotracers.

19 nto the development of new TSPO-specific PET radiotracers.

20 lar in magnitude to many other (18)F-labeled radiotracers.

21 d solutions of the most common PET and SPECT radiotracers.

22 ance of MPI with low-dose and ultra-low-dose radiotracers.

23 esion confirm their potential as in vivo PET-radiotracers.

24 ore, these studies have only used antagonist radiotracers.

25 2.5-fold increase over baseline for both PET radiotracers.

26 , a known characteristic for exendin-4-based radiotracers.

27 e chiral (18)F synthons for the synthesis of radiotracers.

28 after injection in comparison to the other 2 radiotracers.

29 erformed to assess the bioequivalence of all radiotracers.

30 onvenient synthon for labeling potential PET radiotracers.

31 milar kinetic and binding profiles for the 2 radiotracers.

32 ating the in vivo behavior of antibody-based radiotracers.

33 essibility and short half-lives of perfusion radiotracers.

34 nt in vitro studies suggested that the novel radiotracer 1-(2-(18)F-fluoroethyl)-l-tryptophan ((18)F-

35 umor uptake of fructose metabolism-targeting radiotracers 1-[(18)F]FDF, 6-[(18)F]FDF, and 1-[(18)F]FD

36 -labeled prosthetic as a potential (18)F-PET radiotracer (1) or a fluorescence probe (2) for internal

37 re compared with (18)F-FBA -labeled A20FMDV2 radiotracers (1- 3) bearing either no PEG or different P

38 and can be imaged by PET using the selective radiotracer (11)C-(R)PK11195.

39 We developed and evaluated the radiotracer (11)C-BMT-136088 (1-(4'-(3-methyl-4-(((1(R)-

40 nthesis and characterization of the SV2A PET radiotracer (11)C-UCB-J ((R)-1-((3-((11)C-methyl-(11)C)p

41 sis and cerebral glucose metabolism with the radiotracers (11)C-Pittsburgh compound-B (PIB), (11)C-de

42 bility in the VS with the use of the agonist radiotracer [(11)C]-(+)-PHNO (n = 26) and the antagonist

43 g positron emission tomography and the MAO-A radiotracer [(11)C]clorgyline.

44 We used the radiotracer [(11)C]DAA1106 (a ligand for TSPO) and posit

45 PET imaging using the second-generation TSPO radiotracer [(11)C]DPA-713 revealed a strong trend towar

46 ) and positron emission tomography using the radiotracer [(11)C]FLB457 before and after amphetamine t

47 ) before administration of the KOR selective radiotracer [(11)C]GR103545.

48 D2/3 agonist positron emission tomography radiotracer [(11)C]N-propyl-norapomorphine ([(11)C]NPA)

49 the cannabinoid receptor-1 (CB1R) selective radiotracer [(11)C]OMAR on the high resolution research

50 ography and the selective mu-opioid and D2/3 radiotracers [(11)C]carfentanil and [(11)C]raclopride ha

51 administered 1 min prior to injection of the radiotracer, [(11)C]GR103545 binding potential (BPND) wa

52 aphy and the micro-opioid receptor-selective radiotracer [11C]carfentanil after each 1-week inactive

53 with the positron emission tomography (PET) radiotracer [11C]PBR28, which binds to translocator prot

54 this problem by identifying and describing a radiotracer, [11C]GV1-57, that appears to specifically l

55 Here, we have evaluated a PET radiotracer, [11C]GV1-57, that specifically binds mature

56 uptake were observed when the CD20-specific radiotracers (125)I-Fab-ABD and (125)I-Fab-PAS200 were a

57 ivo The pharmacologic properties of the PARP radiotracer [(125)I] KX1: was characterized in multiple

58 ate the role of the synthetic amino acid PET radiotracer (18)F-fluciclovine in modifying the defined

59 To prepare and evaluate a new radiotracer (18)F-IRS for molecular imaging mutant EGF R

60 erwent positron emission tomography with the radiotracer [(18)F]fluoro-l-DOPA to quantify striatal pr

61 s to evaluate if the recently introduced PET radiotracer [(18)F]tetrafluoroborate ([(18)F]BF4(-)) is

62 We assessed the radiotracer 18F-AV-1451 with positron emission tomograph

63 btype) availability using PET imaging of the radiotracer 2-(18)F-fluoro-3-(2(S)-azetidinylmethoxy)pyr

64 Here, we show that a novel PET radiotracer, 2'-deoxy-2'-[18F]fluoro-9-beta-D-arabinofur

65 ting (T87) tumor phenotype using 2 different radiotracers, 2 different image reconstruction algorithm

66 The radiotracer 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT

67 A mass balance method and a radiotracer, (32)P (as H3PO4), were used to investigate

68 lts for the novel estrogen receptor (ER) PET radiotracer 4-fluoro-11beta-methoxy-16alpha-(18)F-fluoro

69 The bi-PEGylated radiotracer 5 showed a greatly improved pharmacokinetic

70 d adjuvant arthritis mice model, whether the radiotracer (99m)Tc-N-(triethylammonium)-3-propyl-[15]an

71 n emission computed tomography imaging and a radiotracer ((99m)Tc-labeled rhesus immunoglobulin G1 an

72 One hour after injection of either radiotracer, a head-to-thigh static scan with a 2-min ac

73 To develop such a technique, a suitable radiotracer able to deliver a beta- emitter to the tumor

74 t of intraoperative detectors that can image radiotracers accumulated within tumors, thus facilitatin

75 with the amount of time required for kidney radiotracer activity to fall by 50% after intravenous ad

76 red in response to both intravenous and oral radiotracer administration.

77 ide-treated mice at 15, 30, and 60 min after radiotracer administration.

78 went PET/CT with (68)Ga-DOTA-E-[c(RGDfK)](2) radiotracer and blood-sample tests to quantify angiogene

79 we developed a (18)F-labeled small molecule radiotracer and investigated its in vivo pharmacokinetic

80 A single hybrid probe combining radiotracer and optical dye would enable high-resolution

81 obtained using PET/CT guidance contain bound radiotracer and therefore provide information about trac

82 tion, should enable their theranostic use as radiotracers and as photothermal probes in tumor ablatio

83 optimization and performance with different radiotracers and time-of-flight imaging.

84 ith [(11)C]FLB457, a dopamine D2/D3 receptor radiotracer, and positron emission tomography (PET).

85 The chemistry and biology of such radiotracers, and the clinical and prognostic impact of

86 gs; in 32 (30.8%), on the findings with both radiotracers; and in 50 (48.1%), on the (68)Ga-DOTATATE

87 ptake of the synthetic amino acid analog PET radiotracer anti-3-(18)F-FACBC ((18)F-fluciclovine) in b

88 Of the synthetic amino acid-derived PET radiotracers, anti-1-amino-3-(18)F-fluorocyclobutane-1-c

89 ation dynamics in lotic food webs, we used a radiotracer approach to characterize accumulation in per

90 In this new approach, intracellular radiotracers are imaged on a conventional fluorescence m

91 are many, positron emission tomography (PET) radiotracers are still available only as research tools.

92 Radiotracers are widely used to track molecular processe

93 includes physiologic biodistribution of the radiotracer, as well as conditions that engender false-p

94 ular disorders by use of a validated ex-vivo radiotracer assay that involved incubation of cholestero

95 mino acid fluxes via VRAC were quantified by radiotracer assays in cells challenged with hypoosmotic

96 We used an RNAi approach and radiotracer assays to explore which LRRC8 isoforms contr

97 Radiotracers based on the peptide A20FMDV2 selectively t

98 Here we describe a radiotracer-based method that addresses this issue, usin

99 (198)Au is used as a radiotracer because it simultaneously emits beta and gam

100 This is feasible if radiotracer binding is measured when postchallenge DA le

101 ters is based on pharmacokinetic modeling of radiotracer biodistribution, which requires the blood in

102 mitate kinetics and an intravenous palmitate radiotracer bolus/timed biopsy.

103 al relative to nondisplaceable uptake of the radiotracer, BPnd) (in 31 methamphetamine users and 37 c

104 anoparticle constructs have been utilized as radiotracers, but irrespective of the particle class, ra

105 T with selective adenosine 2A receptor (A2A) radiotracers can be used to study a variety of neurodege

106 ion tomography with the dopamine D2 receptor radiotracer carbon 11-labeled FLB457 before and after am

107 using the positron emission tomographic D2/3 radiotracer carbon 11-labeled FLB457 in combination with

108 The influence of CBF and radiotracer clearance changes on amyloid-beta load estim

109 mulations showed a limited impact of CBF and radiotracer clearance changes on multilinear reference t

110 re performed to assess the effect of CBF and radiotracer clearance changes on SUVRs and noninvasive k

111 ond, to assess the impact of CBF changes and radiotracer clearance on SUVRs and noninvasive kinetic m

112 d by changes in cerebral blood flow (CBF) or radiotracer clearance.

113 te analysis using the combined data from all radiotracers clearly separated the different groups alon

114 positron emission tomography (PET) using D2R radiotracers combined with psychostimulant challenge.

115 owed quantitative bias for the assessment of radiotracer concentration when bone was ignored.

116 contiguous acquisition steps, corrected for radiotracer decay and injected dose, and fitted to a bic

117 Injection of free radiotracer demonstrated a faster clearance of (18)F-FLT

118 Radiotracer design modifications included chelate, glyco

119 (18)F-DCFBC, a small-molecule PSMA-targeted radiotracer, detected more lesions than CIM and promises

120 (18)F-T807 is a PET radiotracer developed for imaging tau protein aggregates

121 (123)I-CLINDE is a radiotracer developed for SPECT and targets the 18-kDa t

122 ligands with affinity for the same site, in radiotracer development.

123 Radiotracer distribution and dosimetry was determined us

124 metric maps of tumor hypoxia, perfusion, and radiotracer distribution volume.

125 ucted to yield high-resolution images of the radiotracer distribution.

126 tors, allowing for significant reductions in radiotracer dose or acquisition time.

127 The groups did not differ in injected radiotracer dose or body weight, which were used to calc

128 model, significantly longer retention of the radiotracer during (18)F-FDG lymphography was seen in me

129 The backbone-modified radiotracers exhibited a significantly increased resista

130 ability to bind cell surface PSMA, and both radiotracers exhibited selective uptake into PSMA-positi

131 Results from radiotracer experiments were consistent with the roc40 m

132 A novel PET radiotracer, Flurpiridaz F 18, has undergone phase II cl

133 their activities were determined by fructose radiotracer flux.

134 bring data in favor of the (99m)Tc-NTP 15-5 radiotracer for assessing, in vivo, cartilage remodeling

135 ed (18)F-FDG, (99m)Tc-rhAnnexin V-128, or no radiotracer for autoradiography.

136 the initial competition phase between DA and radiotracer for binding to D2R.

137 a direct competition of gemcitabine with the radiotracer for cellular uptake.

138 (89)Zr-DFO-AC-10 is a promising CD30-imaging radiotracer for clinical translation in patients with va

139 mycin holds promise as a noninvasive imaging radiotracer for early treatment evaluation in the clinic

140 r study to target VX2 tumor and serve as the radiotracer for follow-up single-photon emission compute

141 We have developed a metabolically activated radiotracer for functional imaging of P-gp/BCRP activity

142 (18)F-MNI-444 is a useful PET radiotracer for imaging A2A in the human brain.

143 ivo evaluation of (18)F-MNI-444, a novel PET radiotracer for imaging A2A, in healthy human subjects.

144 Compound 16 is a promising radiotracer for imaging CB2 in rodents.

145 There is currently no ideal radiotracer for imaging of protein synthesis rate (PSR)

146 develop and evaluate preclinically a (68)Ga radiotracer for imaging PSMA expression that could be ra

147 acterial accumulation, make it an attractive radiotracer for infection imaging in clinical practice.

148 We are planning to use this radiotracer for investigating NMDA receptor function in

149 2-(18)F-FEtOH is a novel (18)F-based radiotracer for investigating tumor perfusion with PET i

150 use as a positron emission tomography (PET) radiotracer for noninvasive detection of lung inflammati

151 t clinical validation of p5+14 as an amyloid radiotracer for patients in the US.

152 Conclusion:(11)C-sarcosine is a novel radiotracer for PATs and shows initial utility for prost

153 (68)Ga-pentixafor is a radiotracer for PET that binds with nanomolar affinity t

154 Radiocaine, an F-18 radiotracer for positron emission tomography (PET), is t

155 PET)/computed tomography (CT) is a promising radiotracer for quantitative assessment of bone metastas

156 (11)C-JNJ-54173717 is a high-affinity radiotracer for the human P2X7R (hP2X7R).

157 8)F-LY2459989 appears to be an excellent PET radiotracer for the imaging and quantification of the KO

158 des, designated p5 and p5+14, as alternative radiotracers for detecting systemic amyloidosis.

159 the translation of small engineered protein radiotracers for imaging human immune checkpoints.

160 eviously developed several (11)C-labeled PET radiotracers for KOR imaging in humans.

161 This process has potential for preparing new radiotracers for molecular imaging with positron emissio

162 le reagent for developing new (18)F-labelled radiotracers for PET imaging.

163 Current radiotracers for PET of hNIS expression are limited to (

164 Current radiotracers for PET of hNIS expression are limited to (

165 g because of the use of this radionuclide in radiotracers for positron emission tomography (PET).

166 ractive platforms for building multimodality radiotracers for SPECT/MRI and PET/MRI.

167 ed with radioisotopes are being developed as radiotracers for the detection and phenotyping of diseas

168 their development and application as [(18)F]radiotracers for the study of S1PR biodistribution and i

169 11)C-elacridar and (11)C-tariquidar are safe radiotracers, for which an injected activity of 400 MBq

170 Metabolite analysis of the four radiotracers found [(123)I]41 and [(123)I]53 to be the m

171 e kinetic data showed rapid clearance of the radiotracer from the blood pool and most organs, except

172 Treatment with radiotracers had no significant effects on extent of ath

173 ing in non-human primates confirms that this radiotracer has high brain permeability.

174 application of these second-generation TSPO radiotracers has revealed additional problems, including

175 These radiotracers have been utilized in preclinical and clini

176 89 as the first (18)F-labeled KOR antagonist radiotracer in nonhuman primates and its comparison with

177 ted excellent characteristics as an SV2A PET radiotracer in nonhuman primates.

178 Uptake of the radiotracer in tumors was concordant with levels of DLL3

179 nalization and the resulting accumulation of radiotracers in cells is necessary for efficient tumor t

180 distribution and radiation dosimetry of both radiotracers in humans.

181 characteristics of selected hexose-based PET radiotracers in murine BC model EMT6.

182 and BxPC-3 (alphavbeta6+), we evaluated the radiotracers in vitro (serum stability; cell binding and

183 In vitro, radiotracer incorporation and efflux was similar with no

184 red in biodistribution studies 285 min after radiotracer injection (percentage injected dose per gram

185 ivity was determined via PET at 60 min after radiotracer injection.

186 between 0 and 5 min and 15 and 20 min after radiotracer injection.

187 whole-body PET images acquired over 6 h post-radiotracer injection.

188 pheres were injected simultaneously with the radiotracer injections at rest and stress to measure blo

189 em that converts the beta radiation from the radiotracer into photons close to the decay origin throu

190 The radiotracer is currently undergoing first-in-human evalu

191 fore, we conclude that this first antagonist radiotracer is highly useful for PET studies of KOR.

192 Therefore, this radiotracer is suitable for a first-in-human theranostic

193 PET/CT-guided biopsy using (89)Zr-labeled radiotracers is safe and effective without tracer reinje

194 hese studies, performed with D2/3 antagonist radiotracers, is the failure to provide information abou

195 rived compounds, including metabolism of the radiotracer itself, led to the development of synthetic

196 ted from dynamic acquisitions and reflecting radiotracer kinetics may provide additional information.

197 success of PC treatment with PSMA inhibitor radiotracers leads to several questions from the basic r

198 (18)F-FNDP is a promising PET radiotracer likely to be useful for understanding the ro

199 ifficulties with preparing suitably labelled radiotracers limit its scientific and diagnostic applica

200 ng both [(11)C]DASB and [(18)F]MPPF, two PET radiotracers, marking the serotonin transporter and the

201 Thus, a LPA1 PET radiotracer may be useful for studying lung fibrosis or

202 after diagnostic PET/CT using (89)Zr-labeled radiotracers (mean dose, 180 MBq; range, 126-189 MBq) ta

203 sing tetramethylammonium, as well as earlier radiotracer methods, have shown that the extracellular s

204 tumor imaging features of this last class of radiotracers mirror the upregulation of transmembrane am

205 and validating targeted adrenoceptor-binding radiotracers, namely the heavily weighted flow dependenc

206 (18)F-NaF, a PET radiotracer of bone turnover, has shown potential as an

207 We used (123)I-iodobenzovesamicol, a SPECT radiotracer of the vesicular acetylcholine transporter,

208 and ischemia, rate-pressure product, type of radiotracer or stress agent used, and revascularization

209 support the use of CLI for the evaluation of radiotracer performance.

210 e feasibility of within-suite (89)Zr-labeled radiotracer PET/CT-guided biopsy performed without reinj

211 xisting fluorine-18-labeled amino acid-based radiotracers predominantly visualize amino acid transpor

212 -444, compared with previously developed A2A radiotracers, provide the opportunity to foster global u

213 was performed within a PET/CT suite without radiotracer reinjection.

214 nfluence of alpha-cells on the uptake of the radiotracer remains a matter of debate.

215 The development of antibody-based radiotracers requires extensive characterization of thei

216 l maximum signal intensity (MSI), MSI value, radiotracer retention index (RI, myocardial activity/blo

217 we hypothesise will result in minimal local radiotracer reuptake and allow a more accurate estimatio

218 The radiotracer's biodistribution in mice as well as its ser

219 All three radiotracers selectively bound amyloid in vivo; however,

220 All 3 radiotracers showed affinity similar to soluble fibrin f

221 Using PET imaging with a radiotracer specific for the serotonin transporter (5-HT

222 The optical imaging and radiotracer studies confirmed that glymphatic transport

223 ibution is not typically observed with other radiotracers, such as (18)F-FDG.

224 New radiotracers, such as (68)Ga-DOTA-E-[c(RGDfK)](2), that

225 with naturally occurring amino acid-derived radiotracers, such as l-(11)C-methionine and l-1-(11)C-5

226 attenuation correction (AC), and inaccurate radiotracer SUV estimation can limit future PET/MR clini

227 Radiotracer T1/2 values after diuretic administration di

228 In recent years, several radiotracers targeting the prostate-specific membrane an

229 The (198)Au-radiotracer technique enables rapid quantification freed

230 In this study, the (198)Au-radiotracer technique facilitated creating a trimodality

231 This study aims to establish a (198)Au-radiotracer technique for in vivo tracing, rapid quantif

232 Radiotracer techniques were used to perform measurements

233 compound [(125)I] KX1: as a PARP-1-selective radiotracer that can accurately measure PARP-1 expressio

234 Checking for a radiotracer that can deliver a beta(-) emitter to the tu

235 8)F-fluciclovine) is a leucine analog PET/CT radiotracer that depicts amino acid transport into cells

236 cid ((18)F-fluciclovine) is a leucine analog radiotracer that depicts amino acid transport into cells

237 d that (125)I-iodo-DPA-713, a small-molecule radiotracer that specifically targets macrophages, could

238 steine ((18)F-DCFBC), a low-molecular-weight radiotracer that targets the prostate-specific membrane

239 Radiotracers that are in use or under investigation for

240 ions to study the brain has been the lack of radiotracers that can identify and measure specific type

241 e potential to become a prototype for future radiotracers that can identify other neuronal cell types

242 d pharmacokinetics of the antibody-based PET radiotracers that correlated well with the behavior obse

243 nvolved in cognition and behaviors, by using radiotracers that detect relevant biological reactions.

244 itron emission tomography (PET) imaging with radiotracers that target translocator protein 18 kDa (TS

245 estimated that by administering 3 mBq/kg of radiotracer, the time needed to detect a 0.1-mL remnant

246 that by administering a 3 MBq/kg activity of radiotracer, the time needed to detect a 0.1-mL remnant

247 Clearance of the radiotracer through the kidneys and collection in the bl

248 The physiologic uptake of this new radiotracer throughout the body is described in more det

249 Binding of the radiotracer to BAT sections (but not WAT) in vitro was h

250 ositron emission tomography may be the first radiotracer to reflect the loss of pigmented neurons in

251 We employed Mn-54 radiotracers to characterize the extent and dynamics of

252 : verified in vitro results, validating PARP radiotracers to define PARP-1 enzyme expression as an in

253 locator protein positron emission tomography radiotracer together with amyloid imaging using Pittsbur

254 We estimated the rate constants for radiotracer transfer across the BRB (K1, k2) and total r

255 We estimated the rate constants for radiotracer transfer across the BRB (K1, k2) and total r

256 Both radiotracers underwent fast systemic elimination (half-l

257 We analyzed radiotracer uptake (both membrane-bound and internalized

258 Radiotracer uptake and efflux in hNIS-transduced HCT116-

259 rtery, and assessed the relationship between radiotracer uptake and plaque phenotype or predicted car

260 on seem to be the best option with regard to radiotracer uptake and tumor contrast.

261 administration of ICM led to a reduction in radiotracer uptake by the thyroid, accompanied by a dram

262 bbed droplet radiofluidics, that can measure radiotracer uptake for single cells encapsulated into an

263 the first time, the detection of [(18)F]FDG radiotracer uptake in single cells through fluorescence

264 Radiotracer uptake in the tumors was validated ex vivo u

265 In the salivary glands, neither radiotracer uptake nor NIS protein expression was affect

266 combined findings of grade 2 or 3 myocardial radiotracer uptake on bone scintigraphy and the absence

267 have nonamyloid cardiomyopathies, myocardial radiotracer uptake on bone scintigraphy was >99% sensiti

268 Radiotracer uptake was assessed by (18)F-AH113804 PET im

269 In addition, radiotracer uptake was evaluated in 3 breast cancer mode

270 Minimal radiotracer uptake was present in sEH knock-out mice.

271 Radiotracer uptake was validated ex vivo by gamma-counti

272 Examinations exhibiting focally increased radiotracer uptake were considered positive.

273 cause inaccuracies in the quantification of radiotracer uptake, which negatively affects PET-guided

274 showed a direct correlation between BCM and radiotracer uptake.

275 MBq ( approximately 10 mug) of an engineered radiotracer variant and imaged.

276 Notably, all HAC-PD1 radiotracer variants enabled much earlier detection of h

277 Six HAC-PD1 radiotracer variants were developed and used in preclini

278 de strong preclinical evidence that this new radiotracer warrants further studies that may lead to a

279 In the first 2 parts, the radiotracer was administered using a bolus-plus-infusion

280 The radiotracer was evaluated in vitro and in vivo.

281 )C]flumazenil, a benzodiazepine-specific PET radiotracer, was measured before and after administratio

282 th the recent development of in vivo tau PET radiotracers, we show that Abeta and tau are associated

283 tumor targeting and pharmacokinetics of the radiotracers were also evaluated in HCC827, H1975, H358

284 Until recently, most [(18)F]-radiotracers were generated by the direct attachment of

285 The radiotracers were prepared and radiolabeled on solid pha

286 Radiotracers were synthesized using a known fibrin-bindi

287 (54)Mn radiotracers were used to assess Mn atom exchange betwee

288 hymidine ((18)F-FLT); a clinically available radiotracer which we hypothesise will result in minimal

289 d to the development of synthetic amino acid radiotracers, which are not metabolized and therefore mo

290 This work has focused on fluorinated radiotracers, which would enable wider use and improved

291 PET with a selective SV2A radiotracer will allow characterization of drugs that mo

292 this characteristic can be exploited when a radiotracer with a long half-life, such as 90Y, is used.

293 - or (177)Lu-labeled NeoBOMB1 is a promising radiotracer with excellent tumor uptake and favorable ph

294 ated analogues aiming for an [(18)F]-labeled radiotracer with improved CB2 binding affinity and selec

295 e the differential distribution of (18)F-FLT radiotracer with single-cell precision.

296 hat allow the use of relatively low doses of radiotracers with high sensitivity for even small breast

297 d concentration of most common PET and SPECT radiotracers with high temporal resolution in small bloo

298 25 novel radioligands that aims to identify radiotracers with optimal pharmacokinetic and dosimetric

299 conducted, with the eventual replacement of radiotracers with stable isotopically labeled ones, even

300 All patients tolerated the radiotracer without serious adverse effects.